HOME >> BIOLOGY >> NEWS
Royal Society elects Tom Curran as Fellow

PHILADELPHIA Tom Curran, Ph.D., FRS, took his place alongside such distinguished scientists as Isaac Newton, Charles Darwin and Stephen Hawking with his election last week as a Fellow of the Royal Society of London for Improving Natural Knowledge. The 345-year-old Society is the national academy of science of the United Kingdom. The main criterion for election is scientific excellence.

Dr. Curran, a native of Scotland who enjoys dual, U.K./U.S. citizenship, is chairman of the department of developmental neurobiology at St. Jude Children's Research Hospital in Memphis, Tenn. He served the American Association for Cancer Research as president in 2000. His research focuses on molecular events that control the formation of the brain in mammals, and has shown that deregulated gene expression is a critical factor in the development and progression of cancer.

Early in his career, Dr. Curran discovered the fos oncogene and demonstrated its function in gene regulation. He then illustrated how the activity of nerves in the brain can affect the function of fos. This groundbreaking discovery helped open a new field of study key to explaining how changes in gene activity result in alterations in learning and memory. It was recognized by the AACR in 1993, when Dr. Curran received the AACR Award for Outstanding Achievement in Cancer Research, given annually to an accomplished young investigator in the field who is no more than 40 years old at the time the award is conferred.

His subsequent study of a gene called Reelin led to important new insights into how nerve cells in the developing brain migrate to their final locations to form orderly layers.

More recently, Dr. Curran has linked his interest in brain development to the studies of the molecular basis of cancer. Based on this work, he pioneered laboratory studies of a novel molecule called HhAntag to treat brain cancer without the need for traditional chemotherapy or radiation.


'"/>

Contact: Elizabeth Tait
tait@aacr.org
215-440-9300
American Association for Cancer Research
3-Jun-2005


Page: 1 2

Related biology news :

1. Top Canadian superstring theorist, Rob Myers of PI, inducted into Royal Society
2. Royal Museum to host improbable science event
3. Study in Royal Society journal on link between creativity and mating success
4. Study in Royal Society journal on first observation of giant squid in the wild
5. Study in Royal Society journal on possiblity of human organ regeneration
6. Study in Royal Society journal on worlds only horned rodent
7. Study in Royal Society journal on holly as an indicator of climate change
8. Study in Royal Society journal on heritability of female orgasm
9. UCLA physiologist elected to prestigious British Royal Society
10. Royal Society study on adaptability of fish to warming oceans
11. Study in Royal Society journal on sense of fairness in chimpanzees

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Royal Society elects Tom Curran Fellow

(Date:7/13/2015)... OXFORD, Conn. , Jul. 13, 2015 /PRNewswire/ ... the "Company"), a biometric authentication company focused on ... it has filed provisional patent 62/188684 for ... NXT-ID achieves another new convenient and secure method ... expands new, innovative payment methods, introduced with its ...
(Date:7/9/2015)... July 9, 2015  Unchained Labs just can,t ... acquisition of Avid Nano. Avid Nano designs, develops ... systems.    Also today, Unchained Labs ... easiest to use protein sizing system. The pUNk ... protein,s hydrodynamic size, size distribution, aggregation population and ...
(Date:7/8/2015)... LAKES , N.J. and NEW YORK ... Company) and Guidepoint today announced BD ... start-up healthcare companies with free access to Guidepoint,s expert ... several start-ups that are developing cutting-edge technologies to improve ... a dedicated Guidepoint research manager, each start-up entrepreneur will ...
Breaking Biology News(10 mins):NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3
(Date:7/30/2015)... Ascendis Pharma A/S (Nasdaq: ASND ... TransCon technology to address significant unmet medical needs, ... Phase 2 study to evaluate the safety and ... treatment-naïve, pre-pubertal children with growth hormone deficiency, or ... the top-line results from our Phase 2 pediatric ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... advanced fluid applications and designed for continuous operation up to 1500 bar. The ... ensuring safety, efficiency, and preventing toxic contamination. , The Pony™ NS2006L homogenizer is ...
(Date:7/29/2015)... 29, 2015 US-Australian drug discovery company, Novogen ... it is committed to progressing its ground-breaking technology platforms ... and to ensure the Company delivers the best value ... Iain Ross , said the Company currently had an ... programs, discovery programs and academic partnerships and initiatives, and ...
(Date:7/29/2015)... FRANCISCO , July 29, 2015  AsureQuality ... mobile molecular testing for applications in food and ... hand-held, battery powered real-time PCR device, the Freedom4. ... farm right through to the supermarket shelf for ... This includes involvement in animal disease control and ...
Breaking Biology Technology:Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2
Cached News: